Soleno Therapeutics, Inc. announced that it has initiated a randomized withdrawal period of Study C602, an ongoing open-label extension study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS). The randomized withdrawal period of Study C602 is a multi-center, randomized, double-blind, placebo-controlled study of DCCR in approximately 80 patients with PWS at 17 sites in the U.S. and 5 sites in the U.K. This randomized withdrawal period consists only of patients currently enrolled in Study C602 and will not enroll any new patients. Upon Institutional Review Board/Ethics approvals at their respective sites, patients who consent to participate in the randomized withdrawal period, will be randomized to receive DCCR or placebo for a period of four months.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.08 USD | -1.29% | +2.24% | +4.55% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.55% | 153.22Cr | |
+11.91% | 12TCr | |
+11.60% | 11TCr | |
-4.68% | 2.43TCr | |
-0.82% | 2.2TCr | |
-10.12% | 1.82TCr | |
-42.12% | 1.64TCr | |
-17.47% | 1.56TCr | |
+2.77% | 1.36TCr | |
+34.58% | 1.23TCr |
- Stock Market
- Equities
- SLNO Stock
- News Soleno Therapeutics, Inc.
- Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome